CA CMA - Cardiol Therapeutics Corp CFO
CRDL Stock | CAD 3.19 0.12 3.63% |
Insider
CA CMA is Corp CFO of Cardiol Therapeutics Class
Address | 2265 Upper Middle Road East, Oakville, ON, Canada, L6H 0G5 |
Phone | 289 910 0850 |
Web | https://www.cardiolrx.com |
Cardiol Therapeutics Management Efficiency
The company has return on total asset (ROA) of (0.4535) % which means that it has lost $0.4535 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.9211) %, meaning that it generated substantial loss on money invested by shareholders. Cardiol Therapeutics' management efficiency ratios could be used to measure how well Cardiol Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. As of the 29th of May 2024, Return On Tangible Assets is likely to drop to -0.81. In addition to that, Return On Capital Employed is likely to drop to -1.1. At this time, Cardiol Therapeutics' Non Current Assets Total are very stable compared to the past year. As of the 29th of May 2024, Intangible Assets is likely to grow to about 404.7 K, while Total Assets are likely to drop about 38.4 M.Similar Executives
Showing other executives | INSIDER Age | ||
Glenn Ives | Wheaton Precious Metals | N/A | |
Renee McKenzie | Open Text Corp | 49 | |
R Gillin | Wheaton Precious Metals | 70 | |
Howard CPA | Open Text Corp | 60 | |
PEng PEng | Wheaton Precious Metals | 59 | |
Craig Stilwell | Open Text Corp | N/A | |
Mark McClendon | CCL Industries | N/A | |
Genevive Gosselin | Gildan Activewear | N/A | |
Luc Jobin | Gildan Activewear | 59 | |
P Jenkins | Open Text Corp | 59 | |
Gunther Birkner | CCL Industries | 51 | |
Michael Acedo | Open Text Corp | 43 | |
Jamie Beirnes | Wheaton Precious Metals | N/A | |
Jason Pratt | Waste Connections | 39 | |
John Perkey | Waste Connections | 42 |
Management Performance
Return On Equity | -0.92 | ||||
Return On Asset | -0.45 |
Cardiol Therapeutics Leadership Team
Elected by the shareholders, the Cardiol Therapeutics' board of directors comprises two types of representatives: Cardiol Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Cardiol. The board's role is to monitor Cardiol Therapeutics' management team and ensure that shareholders' interests are well served. Cardiol Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Cardiol Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
Andrew MD, Chief Development | ||
Trevor Burns, Investor Relations | ||
Bernard BSc, Chief Officer | ||
MBA MBA, CEO Pres | ||
David MBA, CEO President | ||
CA CMA, Corp CFO |
Cardiol Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Cardiol Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity | -0.92 | ||||
Return On Asset | -0.45 | ||||
Current Valuation | 186.15 M | ||||
Shares Outstanding | 69 M | ||||
Shares Owned By Insiders | 4.42 % | ||||
Shares Owned By Institutions | 12.99 % | ||||
Number Of Shares Shorted | 53.52 K | ||||
Price To Book | 6.16 X | ||||
Price To Sales | 1,274 X | ||||
Gross Profit | 78.76 K |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cardiol Therapeutics Class. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. You can also try the Companies Directory module to evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals.
Complementary Tools for Cardiol Stock analysis
When running Cardiol Therapeutics' price analysis, check to measure Cardiol Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cardiol Therapeutics is operating at the current time. Most of Cardiol Therapeutics' value examination focuses on studying past and present price action to predict the probability of Cardiol Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cardiol Therapeutics' price. Additionally, you may evaluate how the addition of Cardiol Therapeutics to your portfolios can decrease your overall portfolio volatility.
Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios |